Image of the month

Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis

“…In prior articles that described UC-related PG treated with infliximab, no information was given on the effectiveness of this treatment on the intestinal disease [26, 34, 38, 42, 45, 46, 48, 50]. Regueiro et al [42] reported successful management of a UC patient with a complete healing of PG in 1 week, without recurrence on infliximab maintenance therapy and steroid tapering.…”

“…Further references were extracted from review articles on PG and completed with posters and abstracts from the last 4 years’ European and American international congresses of dermatology and gastroenterology. Table 1 gives details on treatment and outcome for 85 patients reported in 22 articles and 9 abstracts andcategorized in 5 groups according to immunosuppression use [13, 14, 17, 18,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51]. …”

Novel Immunotherapies for Psoriasis: Clinical Research Delivers New Hope for Patients and Scientific Advances

“…There are case reports and small series of patients with other immune-mediated in£ammatory diseases treated successfully with TNF-targeting immunotherapies (in£iximab). These include uveitis, Sj˛gren's syndrome, giant cell arteritis, graft versus host disease, sarcoidosis, hidradenitis suppurativa, and pyoderma gangrenosum (Chaudhari et al, 2001;Oh et al, 2000;Braughman and Lower, 2001;Botros et al, 2000;Braun et al, 2002;Cambell and Ghosh, 2001;Couriel et al, 2000;De Clercq, 1987;Fabrizio et al, 2001;Gorman et al, 2002;Martinez et al, 2001;Schothorst et al, 1991;Smith et al, 2001;Steinfeld et al, 2001;Tan et al, 2001). Rather than considering these disorders as separate and localized to nonoverlapping therapeutic areas, perhaps we should group these diseases by common pathogenesis.…”